Fifty Years of Progress Against Cancer
For example, EORTC trial 22981/26981 led to a global platform of four large Phase III trials in patients with brain tumours, and involved EORTC, the Radiation Therapy Oncology Group, the North Central Cancer Treatment Group and the National Cancer Institute of Canada. The MINDACT trial, for patients with breast cancer, is co-ordinated by EORTC and run under the BIG/TRANSBIG networks. It aims to provide confirmatory evidence that patients with a low recurrence risk signature (obtained using MammaPrint: Agendia; Irvine, CA) may be spared chemotherapy and its burdensome side effects without negative repercussions on survival rates. MINDACT involves sites in the Netherlands, France, Germany, Belgium, Spain, Italy, the UK, Slovenia and Switzerland, and has recruited over 6,600 patients in 111 institutions. The first results are expected in approximately three years.
Over the past 50 years, EORTC research has resulted in new benchmark treatments for patients with cancer. The organisation plans to continue to further its mission to develop, conduct,
1. Bernier J, Domenge C, Ozsahin M, et al., European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer, N Engl J Med, 2004;350:1945–52.
2. Bolla M, Van Tienhoven G, Warde P, et al., External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study, Lancet Oncol, 2010;11:1066–73.
3. Trimbos JB, Vergote I, Bolis G, et al., Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma. European Organisation for Research and Treatment of Cancer. Adjuvant chemotherapy in ovarian neoplasm trial, J Natl Cancer Inst, 2003;95(2):113–24.
4. Trimbos JB, Parmar M, Guthrie D, et al., International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma, J Natl Cancer Inst, 2003;95:105–12.
5. Colombo N, Guthrie D, Parmar M, et al.,International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer, J Natl Cancer Inst, 2003;95:125–32.
6. Trimbos B, Timmers P, et al., Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial, J Natl Cancer Inst, 2010;102:982–7.
7. Van Dongen JA, Voogd AC, Fentiman IS, et al., Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial, J Natl Cancer Inst, 2000;92:1143–50.
9. Bartelink H, Horiot JC, Poortmans PM, et al., Impact of a higher radiation dose on local control and survival in breast- conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial, J Clin Oncol, 2007;25:3259–65.
9. Bartelink H, Horiot JC, Poortmans PM, et al., Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation, N Engl J Med, 2001;345:1378–87.
10. Julien JP, Bijker N, Fentiman IS, et al., Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853, Lancet, 2000;355:528–33.
11. Van den Bent MJ, Carpentier AF, Brandes AA, et al., Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial, J Clin Oncol, 2006;24:2715–22.
12. Slotman B, Faivre-Finn C, Kramer G, et al., Prophylactic cranial irradiation in extensive small-cell lung cancer, N Engl J Med, 2007;357:664–72.
13. Le Pechoux C, Dunant A, Senan S, et al., Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial, Lancet Oncol, 2009;10:467–74.
coordinate and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival rates and patient QoL.
Further therapeutic advances will most likely arise from a clinical trial platform that incorporates strong translational research, imaging, biobanking, quality assurance in radiotherapy and in surgery, and research studies aimed at understanding the biology of the disease. This will lead to the development of specific treatments for a fragmented disease that was previously seen as a single entity.
This effort will involve the formation of partnerships with a variety of stakeholders, certainly with other academic groups and learned societies, but also patient organisations, cancer leagues, regulatory agencies and the pharmaceutical industry. In this way, EORTC will ensure that it continues to provide improved treatments for patients with cancer. n
14. Lefebvre J-L, Chevalier D, Luboinski B, et al., Larynx preservation in hypopharynx and lateral epilarynx cancer: Preliminary results of EORTC randomized phase III trial 24891, J Natl Cancer Inst, 1996;88:890–9.
15. Raemaekersa J, Kluin-Nelemans H, Teodorovic I, et al. on behalf of the EORTC Lymphoma Group, The achievements of the EORTC Lymphoma Group, Eur J Cancer, 2002;38:S107–13.
16. Eghbali H, Raemaekers J, Carde P, The EORTC strategy in the treatment of Hodgkin's lymphoma, Eur J Haematol, 2005;66:135–40.
17. Duval M, Suciu S, Ferster A, et al. for the European Organisation for Research and Treatment of Cancer- Children’s Leukemia Group, Comparison of E. coli- asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies, results of an EORTC-CLG Phase III randomized trial, Blood, 2002;99:2734–9.
18. Verweij J, Casali PG, Zalcberg J, et al., Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial, Lancet, 2004;364:1127–34.
19. Stupp R, Mason WP, van den Bent MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 2005;352:987–96.
20. Smit EF, van Meerbeeck J, Lianes P, et al., Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-- EORTC 08975, J Clin Oncol, 2003;21:3909–17.
21. Mandelli F, Vignetti M, Suciu S, et al., Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA groups study AML-10, J Clin Oncol, 2009;27:5397–403.
22. Eggermont AMM, Suciu S, Santinami M, et al. for the EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial, Lancet, 2008;372:117–26.
23. Lübbert M, Suciu S, Baila L, et al., Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized Phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group, J Clin Oncol, Published online before print April 11, 2011, doi:10.1200/JCO.2010.30.9245
24. Schimpff SC, Gaya H, Klastersky J, et al., Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients. The EORTC International Antimicrobial Therapy Project Group, J Infect Dis, 1978;137:14–29.
25. Herbrecht R, Denning DW, Patterson TF et al., Voriconazole versus amphotericin b for primary therapy of invasive aspergillosis, N Engl J Med, 2002:347:408–15.
26. Boellaard R, O’Doherty MJ, Weber WA, et al., FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0, Eur J Nucl Med Mol Imaging, 2010;37:181–200.
27. Hegi ME, Diserens AC, Gorlia T, et al., MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med, 2005;352:997–1003.
28. Rustin GJ, van der Burg MEL, Griffin CL, et al., Early versus delayed treatment of relapsed ovarian cancer (MRC
OV05/EORTC 55955): a randomised trial, Lancet, 2010;376:1155–63.
29. Langemeijer SMC, Kuiper RP, Berends M, et al., Acquired mutations in TET2 are common in myelodysplastic syndromes, Nature Genetics, 2009;41:838–43.
30. Nikoloski GN, Langemeijer SMC, Kuiper RP, et al., Somatic mutations of the histone methyltransferase EZH2 gene in myelodysplastic syndromes, Nature Genetics, 2010;42:665–7.
31. Cavé H, Van Der Werff Ten Bosch J, Suciu S, et al. for the EORTC-Childhood Leukemia Cooperative Group, Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia, N Engl J Med, 1998;339:591–8.
32. Bottomley A, Aaronson NK, International perspective on health-related quality-of-life research in cancer clinical trials: The European Organisation for Research and Treatment of Cancer experience, J Clin Oncol, 2007;25:5082–6.
33. Bottomley A, Quinten C, Coens C, et al., Patient reported outcomes: Assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicine Agency, Eur J Cancer, 2009;45:347–53.
34. Vilmer E, Suciu S, Ferster A, et al., Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group, Leukemia, 2000;14:2257–66.
35. Aaronson NK, Ahmedzai S, Bergman B, et al., The EORTC QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 1993;85:365–76.
36. Willemze R, Jaffe ES, Burg G, et al., WHO-EORTC classification for cutaneous lymphomas, Blood, 2005;105:3768–85.
37. Trautinger F, Knobler R, Willemze R, et al., EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome, Eur J Cancer, 2006;42:1014–30.
38. Olsen EA, Whittaker S, Kim YH, et al., Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer, J Clin Oncol, 2011;29:2598–607.
39. Olsen E, Vonderheid E, Pimpinelli N, et al., Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC), Blood, 2007;110:1713–22.
40. Ascioglu S, Rex JH, de Pauw B, et al., Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus, Clin Infect Dis, 2002;34:7–14.
41. Pallis AG, Fortpied C, Wedding U, et al., EORTC elderly task force position paper: approach to the older cancer patient, Eur J Cancer, 2010;46:1502–13.
42. Pallis AG, Ring A, Fortpeid C, et al., EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors, Ann Oncol, 2011;22:1922–6.
43. Van der Ploeg APT, van Akkooi ACJ, Rutkowski P, et al., Prognosis in patients with sentinel node–positive melanoma is accurately defined by the combined rotterdam tumor load and dewar topography criteria, J Clin Oncol, 2011;29:2206–14.
EUROPEAN ONCOLOGY & HAEMATOLOGY
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77